Drug Profile


Alternative Names: LJM-716; NOV-6

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours

Most Recent Events

  • 02 Aug 2017 Novartis completes a phase I trial in Breast cancer and Gastric cancer (combination therapy, metastatic disease) in USA, United Kingdom, Belgium, France, Italy, Netherlands, Spain, Taiwan and South Korea (IV) (NCT01602406)
  • 27 Jan 2017 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease) in South Korea, Italy, USA, United Kingdom, Netherlands, Belgium, France, Spain, Taiwan (IV) (Novartis 20-F filed in 2017)
  • 27 Jan 2017 Discontinued - Phase-I for Breast cancer in Taiwan, South Korea, USA, Canada, Spain (IV) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top